The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Celltrion's Remsima and Hospira's Inflectra. Both drugs are biosimilar versions of Remicade, an injectable rheumatoid arthritis treatment from Johnson & Johnson and Merck.
2 biosimilar versions of Remicade win EU panel support
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Chief, Product Review Branch||
FDA/Center for Biologics Evaluation and Research
|Silver Spring, MD|
|Director of Clinical Research||
Regenesis Biomedical, Inc.